Novo Nordisk's pre-market decline narrows to 20%
xinhui123
发表于 2024-12-20 20:29:08
3330
0
0
The pre-market decline of Novo Nordisk's US stock market narrowed to 20%, after a sharp drop of nearly 30% at one point, marking the largest single day decline on record, as the trial results of Novo Nordisk's weight loss drug CagriSema fell short of expectations.
CandyLake.com 系信息发布平台，仅提供信息存储空间服务。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
转播
猜你喜欢
- Beike US stock rose more than 2.8% before trading
- Oracle's US stock fell more than 8% in pre-market trading
- Oracle's US stock fell more than 8% in pre-market trading
- Novo Nordisk: All regulatory delivery conditions for Novo Nordisk's $16.5 billion acquisition of Contante have been met
- Novo Nordisk invests 8.5 billion Danish kroner to build new production facility in Odense, Denmark
- Nvidia's US stock fell more than 2% before trading
- Nvidia's US stock rose over 2% in pre-market trading
- Global markets: US stocks close sharply lower, Nasdaq falls more than 3%, Dow Jones Industrial Average falls for ten consecutive years, setting a record for the longest consecutive decline in 50 years
- Tesla's US stock rose more than 3% before trading
- Novo Nordisk's pre-market decline narrowed to 20%, with a previous drop of nearly 30% being the largest single day decline on record
